RxDoctor Payments DataLook up a doctor →

Jahangir Imani, MD

Internal Medicine · Washington Terrace, UTNPI 1063414969

Payments from drug & device makers

$19,097in general payments, 2019–2025

Across 1,031 payments — averaging $18.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • UCB, Inc.$2K
  • EMD Serono, Inc.$2K
  • Biogen$1K
  • Biohaven Pharmaceuticals, Inc.$1K
  • AbbVie$1K
  • Neurocrine Biosciences, Inc.$1K
  • plus $11K from 54 others

What the payments were for

  • Consulting fees$1,2006%
  • Speaking & faculty fees$170%
  • Food & beverage$17,83793%
  • Education$440%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
UCB, Inc.76$1,813
EMD Serono, Inc.94$1,630
Biogen77$1,431
Biohaven Pharmaceuticals, Inc.6$1,298
AbbVie(2 entities)79$1,232
Neurocrine Biosciences, Inc.60$1,082
AstraZeneca47$969
Bristol Myers Squibb49$722
Teva Pharmaceuticals USA, Inc.70$703
Lilly USA, LLC47$703
Sanofi25$517
Collegium Pharmaceutical, Inc.34$508
Livanova USA, Inc.25$491
Johnson & Johnson(2 entities)24$466
Argenx US, Inc.21$466
SK Life Science, Inc.15$352
Lundbeck LLC19$336
Eisai Inc.16$326
Supernus Pharmaceuticals, Inc.32$313
Upsher-smith Laboratories LLC19$310
Boston Scientific14$308
Neurelis, Inc.14$246
Amneal Pharmaceuticals LLC14$239
Amgen12$236
CSL Behring14$214
Takeda Pharmaceuticals U.S.A., Inc.7$180
Acadia Pharmaceuticals Inc9$177
Zyla Life Sciences, Inc.21$163
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC9$142
Pfizer6$139
Harmony Biosciences LLC5$130
TG Therapeutics, Inc.5$127
Biodelivery Sciences International, Inc.8$102
Novartis5$93
Genentech USA, Inc.5$81
Jazz Pharmaceuticals Inc.5$77
Sunovion Pharmaceuticals Inc.4$76
Almatica Pharma LLC4$63
Redhill Biopharma Inc.3$56
Biohaven Pharmaceutical Holding Company Ltd.3$51
Arbor Pharmaceuticals, Inc.3$45
Avanir Pharmaceuticals, Inc.2$44
ANI Pharmaceuticals, Inc.2$42
Otsuka America Pharmaceutical, Inc.2$40
Kaleo, Inc.2$35
Scilex Pharmaceuticals Inc.2$33
E.r. Squibb & Sons, L.L.C.1$32
Vanda Pharmaceuticals Inc.1$28
Idorsia Pharmaceuticals US Inc2$27
MDD US Operations, LLC1$23
Vertex1$23
Shionogi Inc2$22
Medtronic1$20
Adamas Pharmaceuticals, Inc.1$19
Cala Health, Inc.1$17
Acorda Therapeutics, Inc1$17
Axsome Therapeutics, Inc.1$16
International Rehabilitative Sciences, Inc1$15
Assertio Therapeutics, Inc.1$15
GE HealthCare1$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$19,097 in reported general payments places this provider in the 90th percentile of 496 internal medicine providers in Utah.

See all internal medicine providers in Utah

Medicare billing

Part B allowed, 2024
$104,234
Medicare patients
201
Services billed
1,382

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BriviactBrivaracetam67$93,262
QuliptaAtogepant42$58,769
Nurtec OdtRimegepant Sulfate14$22,899
BotoxOnabotulinumtoxina17$21,972
Aimovig AutoinjectorErenumab-Aooe31$19,697
Oxtellar XrOxcarbazepine11$15,242
Topiramate ErTopiramate19$13,337
Sumatriptan Succinate75$11,917
Emgality SyringeGalcanezumab-Gnlm11$7,642
Lacosamide43$5,189
BelsomraSuvorexant11$4,813
RytaryCarbidopa/Levodopa13$4,703
Levetiracetam66$3,353
Carbamazepine ErCarbamazepine14$2,520
Tizanidine Hcl127$2,520

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
UCB, Inc.Briviact$1,813$93,26267 claims
AbbVieQulipta, Botox$1,232$80,74159 claims
PfizerNurtec Odt$139$22,89914 claims
Supernus Pharmaceuticals, Inc.Oxtellar Xr$313$15,24211 claims
Amneal Pharmaceuticals LLCRytary$239$4,70313 claims
Upsher-smith Laboratories LLCTopiramate$310$1,654103 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 496 internal medicine providers in Utah.

Other internal medicine in Washington Terrace

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →